Skip to search formSkip to main contentSkip to account menu

BMS-753493

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

EpothilonesFolic Acid
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Application of a stabilizer cocktail of N-ethylmaleimide and phenylmethanesulfonyl fluoride to concurrently stabilize the disulfide and ester containing compounds in a plasma LC-MS/MS assay.
2013
2013
Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent
BMS-753493 is a folate-targeted candidate being developed for the treatment of cancer. As part of preformulation efforts, our aim… 
2010
2010
A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): A first-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent dosed once daily on days 1…
e13005 Background: The high-affinity folate receptor alpha is selectively overexpressed in some epithelial tumors, including… 
2010
2010
Phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): First-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent administered on days 1, 4, 8…
2607 Background: The high-affinity folate receptor alpha is selectively overexpressed in some epithelial tumors, including… 
2008
2008
Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-targeting agent selected for clinical development
2326 Human folate receptor alpha (FR) is selectively overexpressed in certain tumor types, including ovarian, endometrial, renal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)